Drug switch study aims to guide treatment for serious lung disease
NCT ID NCT07013149
Summary
This study is observing what happens when adults with pulmonary arterial hypertension (PAH) switch from one standard medication (ambrisentan) to another (bosentan). Researchers will track 121 patients for 3-6 months to see if this change affects their overall risk score, which predicts disease outlook. The goal is to provide clearer guidance for doctors when they need to change a patient's PAH treatment plan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
InCor - FMUSP
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.